CIÊNCIA X MARKETING - Debatendo seriamente as vacinas contra a COVID

Ciência e pesquisa
contra a propaganda política do Governo Dória

Pesquisadores em todo o mundo estão trabalhando sem parar para encontrar uma vacina contra o SARS-CoV-2, o vírus que causa a pandemia COVID-19. Os especialistas estimam que um processo acelerado de desenvolvimento de vacinas pode acelerar um candidato bem-sucedido ao mercado em aproximadamente 12-18 meses - se o processo ocorrer sem problemas desde a concepção até a disponibilidade no mercado.

Até o momento, apenas uma vacina contra o coronavírus foi aprovada. O Sputnik V - anteriormente conhecido como Gam-COVID-Vac e desenvolvido pelo Instituto de Pesquisa Gamaleya em Moscou - foi aprovado pelo Ministério da Saúde da Federação Russa em 11 de agosto. Os especialistas levantaram uma preocupação considerável sobre a segurança e eficácia da vacina, uma vez que ela ainda não entrou nos ensaios clínicos de Fase 3.

A pandemia criou parcerias público / privadas sem precedentes. A Rede de Ensaios de Prevenção COVID-19 (COVPN) foi estabelecida, que combina redes de ensaios clínicos financiados pelo Instituto Nacional de Alergia e Doenças Infecciosas (NIAID): a Rede de Ensaios de Vacinas de HIV (HVTN), Rede de Ensaios de Prevenção de HIV (HPTN), Infectious Diseases Clinical Research Consortium (IDCRC) e o AIDS Clinical Trials Group.

SBP - Super Batepapo · Playlist - Desvendando a Vacina do Gov. Dória

 

Mostre 102550100 itens

Procura:

	Candidate	Patrocinador	Trial Phase	Instituição	Financiamento
	Vacina inativada	Wuhan Institute of Biological Products; China National Pharmaceutical Group (Sinopharm)	Fase 3	Henan Provincial Center for Disease Control and Prevention	Ministry of Science and Technology, China
	CoronaVac	Sinovac	Fase 3	Sinovac Research and Development Co., Ltd.	Sinovac Research and Development Co., Ltd.
	mRNA-1273	Moderna	Fase 3	Kaiser Permanente Washington Health Research Institute	Operation Warp Speed; NIAID, BARDA ($483 million)
	Ad5-nCoV	CanSino Biologics	Fase 3	Tongji Hospital; Wuhan, China	CanSino Biologics
	Bacillus Calmette-Guerin (BCG) live-attenuated vaccine	University of Melbourne and Murdoch Children’s Research Institute; Radboud University Medical Center; Faustman Lab at Massachusetts General Hospital	Fase 2/3	University of Melbourne and Murdoch Children’s Research Institute; Radboud University Medical Center; Faustman Lab at Massachusetts General Hospital	Murdoch Children’s Research Institute; UMC Utrecht
	AZD1222/Covishield	The University of Oxford; AstraZeneca; IQVIA; Serum Institute of India	Fase 2/3	The University of Oxford, the Jenner Institute	Operation Warp Speed; UK Ministry of Health; The University of Oxford; BARDA
	BNT162	Pfizer, BioNTech	Fase 2/3	Multiple study sites in Europe and North America	Pfizer; BioNTech
	NVX-CoV2373	Novavax	Fase 2b	Novavax	Novavax, CEPI, Department of Defense ($60 million)
	Adjuvant recombinant vaccine candidate	Anhui Zhifei Longcom Biopharmaceutical, Institute of Microbiology of the Chinese Academy of Sciences	Fase 2
	ZyCoV-D	Zydus Cadila	Fase 2	Zydus Cadila
	Covaxin	Bharat Biotech; National Institute of Virology	Fase 2
	BBIBP-CorV	Beijing Institute of Biological Products; China National Pharmaceutical Group (Sinopharm)	Fase 1/2	Henan Provincial Center for Disease Control and Prevention	Ministry of Science and Technology, China
	GX-19	Genexine	Fase 1/2		GenexineGenexine
	Sputnik V	Gamaleya Research Institute, Acellena Contract Drug Research and Development	Fase 1/2	Various	Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation
	Self-amplifying RNA vaccine	Imperial College London	Fase 1/2	Imperial College London	UK Secretary of State for Health; UK Secretary of State for Business, Energy and Industrial Strategy
	LUNAR-COV19	Arcturus Therapeutics and Duke-NUS Medical School	Fase 1/2	Duke-NUS Medical School, Singapore	Arcturus
	INO-4800	Inovio Pharmaceuticals	Fase 1/2	Center for Pharmaceutical Research, Kansas City. Mo.; University of Pennsylvania, Philadelphia	Inovio Pharmaceuticals
	mRNA-based vaccine	CureVac	Fase 1	CureVac	CureVac; German federal government
	SCB-2019	GlaxoSmithKline, Sanofi, Clover Biopharmaceuticals, Dynavax and Xiamen Innovax	Fase 1	Linear Clinical Research (Australia)	CEPI
	COVAX-19	Vaxine Pty Ltd.	Fase 1	Royal Adelaide Hospital	NIAID
	Plant-based adjutant COVID-19 vaccine candidate	Medicago; GSK; Dynavax	Fase 1	Medicago	Medicago
	Molecular clamp vaccine	CSL; The University of Queensland	Fase 1		CEPI; CSL
	V590	Merck; IAVI	Fase 1		BARDA
	GRAd-COV2	ReiThera; Leukocare; Univercells	Fase 1
	bacTRL-Spike	Symvivo	Pre-clinical	Symvivo Corporation	Symvivo Corporation
	PittCoVacc	UPMC/University of Pittsburgh School of Medicine	Pre-clinical	University of Pittsburgh	CEPI
	V591	University of Pittsburgh’s Center for Vaccine Research	Pre-clinical	University of Pittsburgh; Themis Biosciences; Institut Pasteur	Merck
	Ii-Key peptide COVID-19 vaccine	Generex Biotechnology	Pre-clinical	Generex	Generex
	Recombinant vaccine	Vaxart	Pre-clinical	Vaxart	no information
	LineaDNA	Takis Biotech	Pre-clinical	Takis Biotech	Takis Biotech
	Ad26.COV2-S	Johnson & Johnson	Pre-clinical	Johnson & Johnson	Operation Warp Speed; Johnson & Johnson; BARDA
	AdCOVID	Altimmune	Pre-clinical	University of Alabama at Birmingham	Altimmune
	T-COVIDTM	Altimmune	Pre-clinical		Altimmune
	Protein subunit vaccine	University of Saskatchewan Vaccine and Infectious Disease Organization-International Vaccine Centre	Pre-clinical	University of Saskatchewan Vaccine and Infectious Disease Organization-International Vaccine Centre	no information
	Adenovirus-based vaccine	ImmunityBio; NantKwest	Pre-clinical		Operation Warp Speed
	AAVCOVID	Massachusetts Eye and Ear; Massachusetts General Hospital; University of Pennsylvania	Pre-clinical		Wyc Grousbeck; Emilia Fazzalari
	Recombinant vaccine	Sanofi, Translate Bio	Pre-clinical		BARDA
	HaloVax	Voltron Therapeutics, Inc.; Hoth Therapeutics, Inc.	Pre-clinical	MGH Vaccine and Immunotherapy Center
	mRNA-based vaccine	Chulalongkorn University’s Center of Excellence in Vaccine Research and Development	Pre-clinical
	HDT-301	University of Washington; National Institutes of Health Rocky Mountain Laboratories; HDT Bio Corp	Pre-clinical		University of Washington; National Institutes of Health Rocky Mountain Laboratories; HDT Bio Corp
	gp96-based vaccine	Heat Biologics	Pre-clinical	University of Miami Miller School of Medicine
	mRNA lipid nanoparticle (mRNA-LNP) vaccine	CanSino Biologics, Precision NanoSystems	Pesquisa inicial